Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda

Acta Tropica

Volumn 164, Issue , 2016, Pages 329-336

  Kateera, Fredrick ^a,b   Nsobya, Sam L ^c,d   Tukwasibwe, Steven ^c   Hakizimana, Emmanuel ^a   Mutesa, Leon ^e   Mens, Petra F ^b,f   Grobusch, Martin P ^b   van Vugt, Michèle ^b   Kumar, Nirbhay ^g  

^a RWANDA BIOMEDICAL CENTER   (Rwanda)

^b Laboratory of Experimental Internal Medicine   (Netherlands)

^c MULAGO HOSPITAL   (Uganda)

^d MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^e UNIVERSITY OF RWANDA   (Rwanda)

^f ROYAL TROPICAL INSTITUTE   (Netherlands)

^g TULANE UNIVERSITY   (United States)

Author keywords

Chloroquine; Plasmodium falciparum; Polymorphisms; Resistance; Sulfadoxine pyrimethamine

Indexed keywords

CHLOROQUINE; COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; MULTIDRUG RESISTANCE PROTEIN 1; PYRIMETHAMINE PLUS SULFADOXINE; AMODIAQUINE; ANTIMALARIAL AGENT; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PYRIMETHAMINE; SULFADOXINE;

ANTIMALARIAL AGENT; BIOMARKER; DISEASE CONTROL; DISEASE TRANSMISSION; DISEASE TREATMENT; DRUG RESISTANCE; GENOMICS; HEALTH POLICY; MALARIA; MOLECULAR ANALYSIS; PARASITE; POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALLELE; AMPLICON; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; ASSAY; CHILD; CONTROLLED STUDY; DNA EXTRACTION; DRUG EXPOSURE; DRUG USE; EVOLUTIONARY ADAPTATION; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; INFANT; LIGASE DETECTION REACTION FLUORESCENT MICROSPHERE ASSAY; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; NONHUMAN; PFCRT GENE; PFDHFR GENE; PFDHPS GENE; PFMDR1 GENE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREVALENCE; RWANDA; DRUG COMBINATION; DRUG RESISTANCE; GENETICS; KENYA; MALARIA; MALARIA, FALCIPARUM; MALAWI; NEWBORN; PARASITOLOGY; PRESCHOOL CHILD; TANZANIA; TRANSMISSION; UGANDA;

KENYA; MALAWI; RWANDA; TANZANIA; UGANDA;

BACTERIA (MICROORGANISMS); PLASMODIUM FALCIPARUM;

ADOLESCENT; AMODIAQUINE; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; INFANT; INFANT, NEWBORN; KENYA; MALARIA; MALARIA, FALCIPARUM; MALAWI; MALE; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PYRIMETHAMINE; RWANDA; SULFADOXINE; TANZANIA; UGANDA;

EID: 84989172969     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2016.09.008     Document Type: Article

References (63)

1. Alifrangis, M., Lusingu, J.P., Mmbando, B., Dalgaard, M.B., Vestergaard, L.S., Ishengoma, D., et al. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Am. J. Trop. Med. Hyg. 80 (2009), 523–527.
2. Allen, E.N., Little, F., Camba, T., Cassam, Y., Raman, J., Boulle, A., et al. Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial. Malar. J., 8, 2009, 141.
3. Ashley, E.A., Dhorda, M., Fairhurst, R.M., Amaratunga, C., Lim, P., Suon, S., et al. Spread of artemisinin resistance in P. falciparum malaria. N. Engl. J. Med. 371 (2015), 411–423.
4. Baliraine, F.N., Rosenthal, P.J., Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J. Infect. Dis. 204:7 (2011), 1120–1124.
5. Baraka, V., Ishengoma, D.S., Fransis, F., Minja, D.T., Madebe, R.A., Ngatunga, D., Van Geertruyden, J.P., High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. Malar. J., 14, 2016, 439.
6. Braun, V., Rempis, E., Schnack, A., Decker, S., Rubaihayo, J., Tumwesigye, N.M., et al. Lack of effect of intermittent preventive treatment for malaria in pregnancy and intense drug resistance in western Uganda. Malar. J., 14, 2015, 372.
7. Djimde, A.A., Fofana, B., Sagara, I., Sidibe, B., Toure, S., Dembele, D., et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am. J. Trop. Med. Hyg. 78 (2008), 455–461.
8. Dokomajilar, C., Nsobya, S.L., Greenhouse, B., Rosenthal, P.J., Dorsey, G., Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether—lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob. Agents Chemother. 50 (2006), 1893–1895.
9. Dondorp, A.M., Nosten, F., Yi, P., Das, D., Phyo, A.P., Tarning, J., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361 (2009), 455–467.
10. Enosse, S., Magnussen, P., Abacassamo, F., Gómez-Olivé, X., Rønn, A.M., Thompson, R., et al. Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Malar. J., 7, 2008, 115.
11. Eriksen, J., Nsimba, S.E., Minzi, O.M., Sanga, A.J., Petzold, M., Gustafsson, L.L., et al. Adoption of the new antimalarial drug policy in Tanzania—a cross-sectional study in the community. Trop. Med. Int. Health 10 (2005), 1038–1046.
12. Fidock, D.A., et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6 (2000), 861–871.
13. Frank, M., Lehners, N., Mayengue, P.I., Gabor, J., Dal-Bianco, M., Kombila, D.U., et al. A thirteen-year analysis of Plasmodium falciparum populations reveals high conservation of the mutant pfcrt haplotype despite the withdrawal of chloroquine from national treatment guidelines in Gabon. Malar. J., 10, 2011, 304.
14. Frosch, A.E., Venkatesan, M., Laufer, M.K., Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malar. J., 10, 2011, 116.
15. Gahutu, J.B., Steininger, C., Shyirambere, C., Zeile, I., Cwinya-Ay, N., Danquah, I., et al. Prevalence and risk factors of malaria among children in southern highland Rwanda. Malar. J., 10, 2011, 134.
16. Gasasira, A.F., Kamya, M.R., Ochong, E.O., Vora, N., Achan, J., Charlebois, E., et al. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar. J., 9, 2010, 177.
17. Gesase, S., Gosling, R.D., Hashim, R., Ord, R., Naidoo, I., Madebe, R., et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One, 4(2), 2009, e4569.
18. Hailemeskel, E., Kassa, M., Taddesse, G., Mohammed, H., Woyessa, A., Tasew, G., et al. Prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in dhfr and dhps genes of Plasmodium falciparum three years after SP withdrawal in Bahir Dar, Northwest Ethiopia. Acta Trop. 128 (2013), 636–641.
19. Harinasuta, T., Suntharasamai, P., Viravan, C., Chloroquine-resistant falciparum malaria in Thailand. Lancet 2 (1965), 657–660.
20. Harrington, W.E., Mutabingwa, T.K., Muehlenbachs, A., Sorensen, B., Bolla, M.C., Fried, M., et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 9027–9032.
21. Hastings, M.D., Bates, S.J., Blackstone, E.A., Monks, S.M., Mutabingwa, T.K., Sibley, C.H., Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans. R. Soc. Trop. Med. Hyg. 96:6 (2002), 674–676.
22. Humphreys, G.S., Merinopoulos, I., Ahmed, J., Whitty, C.J., Mutabingwa, T.K., Sutherland, C.J., et al. Amodiaquine and artemether—lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob. Agents Chemother. 51 (2007), 991–997.
23. Iriemenam, N.C., Shah, M., Gatei, W., van Eijk, A.M., Ayisi, J., Kariuki, S., et al. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar. J., 11, 2012, 134.
24. Iyer, J.K., Milhous, W.K., Cortese, J.F., Kublin, J.G., Plowe, C.V., Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 358 (2001), 1066–1067.
25. Kain, K.C., Lanar, D.E., Determination of genetic variation within P. falciparum by using enzymatically amplified DNA from filter paper disks impregnated with whole blood. J. Clin. Microbiol. 29 (1991), 1171–1174.
26. Kamugisha, E., Bujila, I., Lahdo, M., Pello-Esso, S., Minde, M., et al. Large differences in prevalence of Pfcrt and Pfmdr1 mutations between Mwanza, Tanzania and Iganga, Uganda-a reflection of differences in policies regarding withdrawal of chloroquine. Acta Trop. 121 (2012), 148–151.
27. Karema, C., Imwong, M., Fanello, C.I., Stepniewska, K., Uwimana, A., Nakeesathit, S., et al. Molecular correlates of high-level antifolate resistance in rwandan children with plasmodium falciparum malaria. Antimicrob. Agents Chemother. 54 (2010), 477–483.
28. Karema, C., Aregawi, M.W., Rukundo, A., Kabayiza, A., Mulindahabi, M., Fall, I.S., et al. Trends in malaria cases, hospital admissions and deaths following scale-up of anti-malarial interventions, 2000–2010, Rwanda. Malar. J., 11, 2012, 236.
29. Khalil, I., Ronn, A.M., Alifrangis, M., Gabar, H.A., Satti, G.M., Bygbjerg, I.C., Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. Am. J. Trop. Med. Hyg. 68 (2003), 586–589.
30. Koenderink, J.B., Kavishe, R.A., Rijpma, S.R., Russel, F.G., The ABCs of multidrug resistance in malaria. Trends Parasitol. 26 (2010), 440–446.
31. Kublin, J.G., Cortese, J.F., Njunju, E.M., Mukadam, R.A., Wirima, J.J., et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 187 (2003), 1870–1875.
32. Laufer, M.K., Thesing, P.C., Eddington, N.D., Masonga, R., Dzinjalamala, F.K., Takala, S.L., et al. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 355 (2006), 1959–1966.
33. LeClair, N.P., Conrad, M.D., Baliraine, F.N., Nsanzabana, C., Nsobya, S.L., Rosenthal, P.J., Optimization of a ligase detection reaction-fluorescent microsphere assay for characterization of resistance-mediating polymorphisms in African samples of plasmodium falciparum. J. Clin. Microbiol. 51 (2013), 2564–2570.
34. Lobo, E., de Sousa, B., Rosa, S., Figueiredo, P., Lobo, L., Pateira, S., et al. Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Malar. J., 13, 2014, 300.
35. Lynch, C., Pearce, R., Pota, H., Cox, J., Abeku, T.A., Rwakimari, J., et al. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J. Infect. Dis. 197 (2008), 1598–1604.
36. Malmberg, M., Ngasala, B., Ferreira, P.E., Larsson, E., Jovel, I., Hjalmarsson, A., et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar. J., 12, 2013, 103.
37. Matondo, S.I., Temba, G.S., Kavishe, A.A., Kauki, J.S., Kalinga, A., van Zwetselaar, M., et al. High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania. Malar. J., 13, 2014, 152.
38. Mbogo, G.W., Nankoberanyi, S., Tukwasibwe, S., Baliraine, F.N., Nsobya, S.L., Conrad, M.D., et al. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am. J. Trop. Med. Hyg. 91:1 (2014), 54–61.
39. Minja, D., Schmiegelow, C., Mmbando, B., Boström, S., Oesterholt, M., Magistrado, P., et al. Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania. Emerg. Infect. Dis. 19:September (9) (2013), 1446–1454.
40. Mohammed, A., Ndaro, A., Kalinga, A., Manjurano, A., Mosha, J.F., Mosha, D.F., et al. Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania. Malar. J., 12, 2013, 415.
41. Mwai, L., Ochong, E., Abdirahman, A., Kiara, S.M., Ward, S., Kokwaro, G., et al. Chloroquine resistance before and after its withdrawal in Kenya. Malar. J., 8, 2009, 106.
42. Nankoberanyi, S., Mbogo, G.W., LeClair, N.P., Conrad, M.D., Tumwebaze, P., Tukwasibwe, S., et al. Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda. Malar. J., 13, 2014, 95.
43. Ndiaye, M., Faye, B., Tine, R., Ndiaye, J.L., Lo, A., Abiola, A., et al. Assessment of the molecular marker of Plasmodium falciparum chloroquine resistance (Pfcrt) in Senegal after several years of chloroquine withdrawal. Am. J. Trop. Med. Hyg. 87:4 (2012), 640–645.
44. Nsobya, S.L., Kiggundu, M., Nanyunja, S., Joloba, M., Greenhouse, B., Rosenthal, P.J., In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob. Agents Chemother. 54 (2010), 1200–1206.
45. Nzila-Mounda, A., Mberu, E.K., Sibley, C.H., Plowe, C.V., Winstanley, P.A., Watkins, W.M., Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob. Agents Chemother. 42 (1998), 164–169.
46. Okombo, J., Kamau, A.W., Marsh, K., Sutherland, C.J., Ochola-Oyier, L.I., Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya. Int. J. Parasitol. Drugs Drug Resist. 4:3 (2014), 152–163.
47. Ord, R., Alexander, N., Dunyo, S., Hallett, R., Jawara, M., Targett, G., et al. Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J. Infect. Dis. 196 (2007), 1613–1619.
48. Pearce, R.J., Pota, H., Evehe, M.S., Bâ el-H, Mombo-Ngoma, G., Malisa, A.L., et al. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med., 6(4), 2009, e1000055.
49. PMI/MOH-Rwanda. President's Malaria Initiative Rwanda Malaria Operational Plan FY 2015. http://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy-15/fy-2015-rwanda-malaria-operational-plan.pdf?sfvrsn=3.
50. Raman, J., Sharp, B., Kleinschmidt, I., Roper, C., Streat, E., Kelly, V., et al. Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. Am. J. Trop. Med. Hyg. 78 (2008), 256–261.
51. Rosenthal, P.J., The interplay between drug resistance and fitness in malaria parasites. Mol. Microbiol. 89 (2013), 1025–1038.
52. Shah, M., Omosun, Y., Lal, A., Lal, A., Odero, C., Gatei, W., Otieno, K., et al. Assessment of molecular markers for anti-malarial drug resistance after the introduction and scale-up of malaria control interventions in western Kenya. Malar. J., 14, 2015, 75.
53. Sisowath, C., Stromberg, J., Martensson, A., Msellem, M., Obondo, C., Bjorkman, A., et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether–lumefantrine (Coartem). J. Infect. Dis. 191 (2005), 1014–1017.
54. Sisowath, C., Petersen, I., Veiga, M.I., Mårtensson, A., Premji, Z., Björkman, A., et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Infect. Dis. 199:March 1 (5) (2009), 750–757.
55. Spalding, M.D., Eyase, F.L., Akala, H.M., Bedno, S.A., Prigge, S.T., Coldren, R.L., et al. Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malar. J., 9, 2010, 338.
56. Su, X., et al. Complex polymorphisms in a ∼330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell 91 (1997), 593–603.
57. Tessema, S.K., Kassa, M., Kebede, A., Mohammed, H., Leta, G.T., Woyessa, A., et al. Declining trend of Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant alleles after the withdrawal of sulfadoxine-pyrimethamine in North Western Ethiopia. PLoS One, 10(10), 2015, e0126943.
58. Triglia, T., Menting, J.G.T., Wilson, C., Cowman, A.F., Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 13944–13949.
59. Vinayak, S., Alam, M.T., Sem, R., Shah, N.K., Susanti, A.I., Lim, P., et al. Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia. J. Infect. Dis. 201 (2010), 1551–1560.
60. White, N.J., Antimalarial drug resistance and combination chemotherapy. Philos. Trans. R Soc. Lond. B Biol. Sci. 354 (1999), 739–749.
61. World Health Organization, World Malaria Report 2015. http://apps.who.int/iris/bitstream/10665/200018/1/9789241565158_eng.pdf.
62. Young, M.D., Moore, D.V., Chloroquine resistance in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 10 (1961), 317–320.
63. Zeile, I., Gahutu, J.B., Shyirambere, C., Steininger, C., Musemakweri, A., Sebahungu, F., et al. Molecular markers of Plasmodium falciparum drug resistance in southern highland Rwanda. Acta Trop. 121 (2012), 50–54.